In combination therapy for treating type 2 diabetes (NICE TA288)
NICE TA288 - Dapagliflozin in combination therapy for treating type 2 diabetes
MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis
Dapagliflozin in a dual therapy regimen in combination with metformin is recommended as an option for treating type 2 diabetes, only if:
a sulfonylurea is contraindicated or not tolerated or
the person is at significant risk of hypoglycaemia or its consequences.
Dapagliflozin in combination with insulin with or without other antidiabetic drugs is recommended as an option for treating type 2 diabetes.
The third recommendation, previously part of this guidance, has been updated and replaced by NICE’s technology appraisal guidance on dapagliflozin in triple therapy for treating type 2 diabetes (TA418)
The LSCMMG recommends dapagliflozin as a 1st line ““gliflozin””.
Reason for decision:
Suitable for initiation in primary care in line with restrictions